Becton, Dickinson and Company $BDX Shares Newly Purchased by Edgestream Partners L.P.

Edgestream Partners L.P. acquired a new position in shares of Becton, Dickinson and Company (NYSE:BDX – Free Report) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 20,139 shares of the medical instruments supplier’s stock, valued at approximately $3,605,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. TD Waterhouse Canada Inc. grew its stake in shares of Becton, Dickinson and Company by 17.1% in the second quarter. TD Waterhouse Canada Inc. now owns 96,211 shares of the medical instruments supplier’s stock worth $14,715,000 after acquiring an additional 14,077 shares during the last quarter. Capital Analysts LLC boosted its stake in Becton, Dickinson and Company by 7.5% in the 2nd quarter. Capital Analysts LLC now owns 83,601 shares of the medical instruments supplier’s stock worth $12,651,000 after purchasing an additional 5,828 shares in the last quarter. Northside Capital Management LLC boosted its stake in Becton, Dickinson and Company by 18.3% in the 2nd quarter. Northside Capital Management LLC now owns 61,324 shares of the medical instruments supplier’s stock worth $9,280,000 after purchasing an additional 9,494 shares in the last quarter. NewEdge Advisors LLC grew its position in Becton, Dickinson and Company by 35.0% during the 1st quarter. NewEdge Advisors LLC now owns 44,032 shares of the medical instruments supplier’s stock valued at $6,923,000 after purchasing an additional 11,414 shares during the last quarter. Finally, Beverly Hills Private Wealth LLC bought a new stake in Becton, Dickinson and Company during the 2nd quarter valued at about $3,353,000. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Stock Down 1.6%

Becton, Dickinson and Company stock opened at $212.72 on Friday. Becton, Dickinson and Company has a one year low of $140.11 and a one year high of $220.36. The stock has a fifty day moving average of $193.71 and a 200 day moving average of $170.82. The company has a debt-to-equity ratio of 0.54, a quick ratio of 0.54 and a current ratio of 0.87. The stock has a market cap of $58.61 billion, a PE ratio of 51.38, a price-to-earnings-growth ratio of 3.62 and a beta of 0.22.

Becton, Dickinson and Company (NYSE:BDX – Get Free Report) last released its quarterly earnings results on Thursday, November 5th. The medical instruments supplier reported $4.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.07 by $0.08. Becton, Dickinson and Company had a return on equity of 14.90% and a net margin of 5.66%. The business had revenue of $5.27 billion during the quarter, compared to the consensus estimate of $5.11 billion. During the same period in the previous year, the company posted $3.96 EPS. The business’s quarterly revenue was up 5.4% compared to the same quarter last year. As a group, sell-side analysts predict that Becton, Dickinson and Company will post 13.21 EPS for the current year.

Becton, Dickinson and Company Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, December 31st. Stockholders of record on Thursday, December 10th will be paid a dividend of $1.06 per share. The ex-dividend date is Thursday, December 10th. This represents a $4.24 annualized dividend and a dividend yield of 2.0%. This is a boost from Becton, Dickinson and Company’s previous quarterly dividend of $1.05. Becton, Dickinson and Company’s dividend payout ratio is 101.45%.

Becton, Dickinson and Company declared that its board has authorized a share buyback program on Thursday, November 5th that permits the company to repurchase 10,000,000 shares. This repurchase authorization permits the medical instruments supplier to buy up to 3.6% of its shares through open market purchases. Stock repurchase programs are usually an indication that the company’s management believes its shares are undervalued.

Wall Street Analysts Forecast Growth

BDX has been the subject of several recent analyst reports. Citigroup lifted their target price on shares of Becton, Dickinson and Company from $208.00 to $241.00 and gave the stock a “buy” rating in a report on Friday, November 6th. Bank of America upped their price objective on Becton, Dickinson and Company from $185.00 to $200.00 and gave the company a “neutral” rating in a research report on Monday, August 31st. Wells Fargo & Company increased their target price on Becton, Dickinson and Company from $161.00 to $170.00 and gave the company an “equal weight” rating in a research note on Friday, August 7th. Weiss Ratings raised Becton, Dickinson and Company from a “hold (c-)” rating to a “hold (c)” rating in a report on Wednesday, November 4th. Finally, UBS Group initiated coverage on Becton, Dickinson and Company in a report on Tuesday, July 28th. They issued a “buy” rating and a $190.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, eight have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $197.47.

Read Our Latest Stock Analysis on Becton, Dickinson and Company

Insiders Place Their Bets

In other news, EVP Michael Feld sold 165 shares of Becton, Dickinson and Company stock in a transaction dated Wednesday, August 26th. The stock was sold at an average price of $188.49, for a total transaction of $31,100.85. Following the transaction, the executive vice president directly owned 19,720 shares of the company’s stock, valued at $3,717,022.80. The trade was a 0.83% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Thomas E. Polen, Jr. sold 2,993 shares of the business’s stock in a transaction that occurred on Thursday, November 5th. The shares were sold at an average price of $210.00, for a total value of $628,530.00. Following the transaction, the chief executive officer owned 110,163 shares of the company’s stock, valued at approximately $23,134,230. This trade represents a 2.65% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 3,310 shares of company stock valued at $688,650. Insiders own 0.40% of the company’s stock.

About Becton, Dickinson and Company

(Free Report)

Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops and manufactures products used in healthcare, clinical laboratories and life sciences research. Founded in 1897, the company has a long history of producing medical devices and supplies. BD’s products include syringes, needles, infusion systems and medication-management technologies, as well as equipment and supplies for collecting and processing clinical specimens. The company also provides diagnostic systems, laboratory instruments and tools used in areas such as cell analysis and biomedical research.

Further Reading

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX – Free Report).

Institutional Ownership by Quarter for Becton, Dickinson and Company (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.